Tech Company Financing Transactions
UNITY Biotechnology Funding Round
UNITY Biotechnology secured a $55 million Series C funding round on 3/20/2018. Investors included 6 Dimensions Capital, Altitude Life Science Ventures and Arch Venture Partners.
Transaction Overview
Company Name
Announced On
3/20/2018
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Series C
Investors
Proceeds Purpose
Proceeds from this financing will be used to advance the company's lead senolytic drug candidates into human clinical trials.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
3280 Bayshore Blvd. 100
Brisbane, CA 94005
USA
Brisbane, CA 94005
USA
Phone
Website
Email Address
Overview
Unity Biotechnology (Nasdaq: UBX) Imagine a future in which you age, but without the diseases your parents got. A future in which it doesn't hurt to grow old. At UNITY, we design therapeutics that prevent, halt, or reverse diseases of aging. Our medicines are designed to lengthen healthspan, the amount of time you live in good health.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Keith Leonard
Chief Financial Officer
Robert Goeltz
Chief Medical Officer
Jamie Dananberg
Chief Scientific Officer
Dan Marquess
President
Nathaniel David
VP - General Counsel
Tamara Tompkins
Browse more venture capital transactions:
Prev: 3/20/2018: PHLUR venture capital transaction
Next: 3/20/2018: SkyCision venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC transactions reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs